SLC5A2 and type 2 diabetes mellitus: Currently, it has been suggested as second-line therapy in T2DM patients the use of sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) for their reno-cardiovascular safety profile [1].